Request Services Now
CTSA

Seminar in Transnational Research (STRECH) - January 18th, 2019

Photo of Dr. Charles FranceMCAM: A Novel Mu Opioid Receptor For Treating Opioid Overdose and Abuse

Charles France, Ph.D.
Robert A Welch Distinguished University Chair in Chemistry
Director, NIH/NIDA T32 - Training in Drug Abuse Research: Behavior and Neurobiology
Professor, Departments of Pharmacology and Psychiatry
Director, Addiction Research Treatment & Training Center of Excellence

Deaths from opioid overdose continue to rise; from 2015-2016, there was a 28% increase in the number of fatal overdoses. Fentanyl derivatives are inexpensive, easy to synthesize, potent, and marketed to unsuspecting abusers as heroin or other drugs. The effects of fentanyl derivatives are reportedly more difficult to reverse with naloxone, compared with reversal of heroin. Pharmacotherapies for opioid abuse include the µ opioid receptor agonists methadone and buprenorphine that are effective in many patients, although both drugs have limitations, including diversion and abuse, and they can have serious unwanted effects, including respiratory depression and death. The opioid receptor antagonists naltrexone and naloxone avoid the abuse liability and adverse effects of methadone and buprenorphine; however, short durations of action and surmountability limit their effectiveness.   Methocinnamox (MCAM) is a new potential medication with a longer duration of action that prevents and reverses the effects of opioids in a manner that is not surmounted by increasing doses of agonist could improve significantly treatment of abuse and save lives by providing insurmountable extended protection after rescue from overdose.

Date: Friday, January 18, 2019 
Time: 9:00 AM - 10:00 AM
Location: UT Health San Antonio, Medical School (MED) 409L

More information here...